Vasopressin and desmopressin in central diabetes insipidus: Adverse effects and clinical considerations

Roy J. Kim, Clara Malattia, Michaela Allen, Thomas Moshang, Mohamad Maghnie

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The management of central diabetes insipidus has been greatly simplified by the introduction of desmopressin (DDAVP). Its ease of administration, safety and tolerabitity make DDAVP the first line agent for outpatient treatment of central diabetes insipidus. The major complication of DDAVP therapy is water intoxication and hyponatremia. The risk of hyponatremia can be reduced by careful dose titration when initiating therapy and by close monitoring of serum osmolality when DDAVP is used with other medications affecting water balance. Herein we review the adverse effects of DDAVP and its predecessor, vasopressin, as well as discuss important clinical considerations when using these agents to treat central diabetes insipidus.

Original languageEnglish
Pages (from-to)115-123
Number of pages9
JournalPediatric Endocrinology Reviews
Volume2
Issue numberSUPPL. 1
Publication statusPublished - Nov 2004

Fingerprint

Neurogenic Diabetes Insipidus
Deamino Arginine Vasopressin
Vasopressins
Hyponatremia
Water Intoxication
Osmolar Concentration
Outpatients
Therapeutics
Safety
Water
Serum

Keywords

  • Adverse effects
  • Children
  • Desmopressin
  • Diabetes insipidus
  • Vasopressin

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Vasopressin and desmopressin in central diabetes insipidus : Adverse effects and clinical considerations. / Kim, Roy J.; Malattia, Clara; Allen, Michaela; Moshang, Thomas; Maghnie, Mohamad.

In: Pediatric Endocrinology Reviews, Vol. 2, No. SUPPL. 1, 11.2004, p. 115-123.

Research output: Contribution to journalArticle

@article{7188c7fcf4ca4ded8ec909e5c02c9e30,
title = "Vasopressin and desmopressin in central diabetes insipidus: Adverse effects and clinical considerations",
abstract = "The management of central diabetes insipidus has been greatly simplified by the introduction of desmopressin (DDAVP). Its ease of administration, safety and tolerabitity make DDAVP the first line agent for outpatient treatment of central diabetes insipidus. The major complication of DDAVP therapy is water intoxication and hyponatremia. The risk of hyponatremia can be reduced by careful dose titration when initiating therapy and by close monitoring of serum osmolality when DDAVP is used with other medications affecting water balance. Herein we review the adverse effects of DDAVP and its predecessor, vasopressin, as well as discuss important clinical considerations when using these agents to treat central diabetes insipidus.",
keywords = "Adverse effects, Children, Desmopressin, Diabetes insipidus, Vasopressin",
author = "Kim, {Roy J.} and Clara Malattia and Michaela Allen and Thomas Moshang and Mohamad Maghnie",
year = "2004",
month = "11",
language = "English",
volume = "2",
pages = "115--123",
journal = "Pediatric Endocrinology Reviews",
issn = "1565-4753",
publisher = "YS Medical Media Ltd.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Vasopressin and desmopressin in central diabetes insipidus

T2 - Adverse effects and clinical considerations

AU - Kim, Roy J.

AU - Malattia, Clara

AU - Allen, Michaela

AU - Moshang, Thomas

AU - Maghnie, Mohamad

PY - 2004/11

Y1 - 2004/11

N2 - The management of central diabetes insipidus has been greatly simplified by the introduction of desmopressin (DDAVP). Its ease of administration, safety and tolerabitity make DDAVP the first line agent for outpatient treatment of central diabetes insipidus. The major complication of DDAVP therapy is water intoxication and hyponatremia. The risk of hyponatremia can be reduced by careful dose titration when initiating therapy and by close monitoring of serum osmolality when DDAVP is used with other medications affecting water balance. Herein we review the adverse effects of DDAVP and its predecessor, vasopressin, as well as discuss important clinical considerations when using these agents to treat central diabetes insipidus.

AB - The management of central diabetes insipidus has been greatly simplified by the introduction of desmopressin (DDAVP). Its ease of administration, safety and tolerabitity make DDAVP the first line agent for outpatient treatment of central diabetes insipidus. The major complication of DDAVP therapy is water intoxication and hyponatremia. The risk of hyponatremia can be reduced by careful dose titration when initiating therapy and by close monitoring of serum osmolality when DDAVP is used with other medications affecting water balance. Herein we review the adverse effects of DDAVP and its predecessor, vasopressin, as well as discuss important clinical considerations when using these agents to treat central diabetes insipidus.

KW - Adverse effects

KW - Children

KW - Desmopressin

KW - Diabetes insipidus

KW - Vasopressin

UR - http://www.scopus.com/inward/record.url?scp=12344258648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12344258648&partnerID=8YFLogxK

M3 - Article

C2 - 16456490

AN - SCOPUS:12344258648

VL - 2

SP - 115

EP - 123

JO - Pediatric Endocrinology Reviews

JF - Pediatric Endocrinology Reviews

SN - 1565-4753

IS - SUPPL. 1

ER -